Tango Therapeutics' Q3 loss widens as revenue drops to zero after Gilead deal ends
TNGX•Tango Therapeutics reported a Q3 net loss of $68.39 million, or $0.39 per share, as collaboration revenue fell to zero after its Gilead partnership ended. Operating expenses were $78.12 million.
1. Q3 results
Tango Therapeutics reported a Q3 net loss of $68.39 million, or $0.39 per share, as collaboration revenue fell to zero following the conclusion of its Gilead partnership. Operating expenses rose to $78.12 million, driven by higher research and development costs for clinical programs and increased administrative expenses.
2. Clinical plans
The company highlighted Phase 1/2 data for its lead drug in pancreatic cancer. Tango expects to start a Phase 3 trial of vopimetostat plus daraxonrasib in the first half of 2027 and plans to discuss accelerated approval for the combination in second-line pancreatic cancer. It expects to disclose vopimetostat lung cancer monotherapy data in January 2027.
